AHA to Novartis Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems

AHA expresses profound concern about actions Novartis Corporation Global, is taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.

Key Resources

Related Resources

Case Studies
UK St. Claire | Kentucky
Public
Advisory
CMS Finalizes Guidance on Implementation of the Medicare Drug Price Negotiation Program
Member
Case Studies
University of Louisville Health | Kentucky
Public
Action Alert
Urge Your Representative to Sign Letter for HHS to Act on J&J 340B Proposal
Member
Guides/Reports
340B Arrangements with Community and Specialty Pharmacies Improve Access to Care for Underserved Patients
Public
Letter/Comment
AHA Urges HRSA to Take Immediate Enforcement Action to Block J&J’s Illegal Imposition of 340B Rebate Model
Public